A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
This is a multicenter, non-randomized (Except for Dose Expansion 1 and Dose Expansion 9 cohorts), open-label, multiple-dose, FIH study. The study consists of two parts: Part 1 adopts an accelerated titration at first dose level followed with classic "3+3" design to identify the MTD/RP2D; Part 2 is a dose expansion phase to confirm the safety, tolerability and explore efficacy in selected malignant solid tumors at the MTD/the RP2D. This study will enroll subjects with advanced/unresectable, recurrent, or metastatic HER2-expressing malignant solid tumors.
Inclusion Criteria:
Additional Inclusion Criteria for Part 2 Expansion Group 9:
1. Has pathologically documented advanced/unresectable, recurrent, or metastatic EC (including UCS and USPC) and has progressed on or after at least 1 line of systemic treatment including platinum-based therapy and exposure to ICI but no more than prior 3 lines of therapy for advanced/unresectable, or metastatic disease. Note: endocrine therapy will not qualify as a systemic therapy line.
Exclusion Criteria:
britney.winterberger@tigermedgrp.com+1-513-403-8568
Washington D.C., District of Columbia 20010, United States
Lakeland, Florida 33812, United States
Honolulu, Hawaii 96826, United States
Boston, Massachusetts 02215, United States
Dearborn, Michigan 48126, United States
New York, New York 10016, United States
Shirley, New York 11967, United States
South Brisbane, Queensland 4101, Australia
Chongqing, Chongqing Municipality, China
Wuhan, Hubei, China
Shanghai, Shanghai Municipality, China
Tianjin, Tianjin Municipality, China
Hangzhou, Zhejiang, China
Gyeonggi-do, Bundang-gu 13620, South Korea
Taipei, Zhonghe District 235041, Taiwan